Eloxatine Progression-Free Survival Data Not Enough For Colorectal Use
Executive Summary
Studies showing an overall survival advantage for Sanofi-Synthelabo's Eloxatine over 5-FU-based chemotherapy would be needed for approval of the agent as first-line therapy for colorectal cancer, FDA's Oncologic Drugs Advisory Committee found March 16.
You may also be interested in...
FDA Support For Survival Endpoints Affirmed At Colon Cancer Workshop
Cancer drug trials will continue to need survival data to receive full approval, FDA suggested at a Nov. 12 workshop on colon cancer endpoints
FDA Support For Survival Endpoints Affirmed At Colon Cancer Workshop
Cancer drug trials will continue to need survival data to receive full approval, FDA suggested at a Nov. 12 workshop on colon cancer endpoints
Sanofi Eloxatin First-Line Colorectal Cancer Data Will Be Submitted By 2003
Sanofi-Synthelabo Eloxatin first-line data in advanced colonic and rectal adenocarcinoma will be submitted to FDA by the third quarter of 2003, following oxaliplatin's approval as second-line use